Lenvatinib plus radiation seeds vs lenvatinib alone for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial compares lenvatinib plus implanted radiation seeds versus lenvatinib alone in people with liver cancer that no longer responds to TACE. It aims to improve how long patients can control the cancer inside the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed liver cancer (HCC) based on biopsy/cytology or a clinician’s diagnosis
- Your liver cancer is considered “TACE-refractory” (TACE is no longer working) and/or the cancer returned after surgery or ablation
- Your scans show at least one measurable tumor in the liver you can treat with the study plan
- Your liver function is good enough for treatment (Child-Pugh A or B)
- You are well enough day-to-day (ECOG 0 or 1) and expected to live at least 3 months
- Your cancer has not spread outside the liver, and there is no major vessel blockage like main portal vein involvement
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for liver cancer (HCC) that has stopped responding to TACE. One group gets lenvatinib (a targeted therapy pill) plus SIRT (internal radiation beads placed in the liver), and the other gets lenvatinib alone. The goal is to see which combination works better.
This study compares a stronger treatment plan (lenvatinib plus sintilimab plus TACE) against a standard plan (lenvatinib plus TACE) for advanced liver cancer. It aims to see which plan works better to control tumors and help patients live longer.
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This trial tests a combination of a focused radiation beam (SBRT) plus a pill that helps stop tumor blood vessel growth (lenvatinib) and a procedure that blocks blood flow to the tumor (TACE) for people with advanced liver cancer that has not yet spread outside the liver. The goal is to see if this triple therapy can improve outcomes without prior treatment.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial compares the combination of two treatments—chemoembolization (TACE) and lenvatinib—against lenvatinib alone for people with liver cancer that cannot be removed by surgery. It aims to see if the combination works better.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.